FDA Withholds Some COVID-19 and Shingles Vaccine Studies Citing Scientific Standards
The Food and Drug Administration withdrew two COVID-19 vaccine studies accepted by medical journals and prevented submission of two Shingrix abstracts, according to The New York Times. HHS confirmed the actions and said the COVID studies were withdrawn because authors drew broad conclusions not supported by the data.
upi.comThe Food and Drug Administration blocked publication of studies finding that COVID-19 and shingles vaccines were safe, The New York Times reported. FDA scientists and data contractors reviewed millions of patient records for the studies that were pulled back before release.
The Department of Health and Human Services confirmed that the FDA blocked the publication of studies showing the safety and efficacy of vaccines against COVID-19 and shingles.
The Centers for Disease Control and Prevention scrapped a scientifically vetted study previously scheduled for publication that found COVID-19 vaccines sharply cut the risk of emergency care and hospitalization among healthy adults. The CDC study was rejected by Robert F. Kennedy’s acting CDC director.
Two studies on COVID-19 vaccines by FDA scientists were accepted for publication at medical journals before unnamed FDA officials directed the agency scientists to withdraw them. A preliminary abstract of one of the COVID-19 vaccine studies was presented at a conference last fall and remains online. The New York Times obtained a copy of the full manuscript of one of the COVID-19 vaccine studies.
FDA officials did not allow agency scientists to submit two abstracts for studies on Shingrix to a major drug safety conference. The two Shingrix studies bolstered known efficacy and safety data of the vaccines. ” Andrew Nixon stated that the FDA acted to protect the integrity of its scientific process and ensure that any work associated with the agency meets its high standards.
Andrew Nixon stated that the design of the Shingrix efficacy study fell outside the agency’s purview. Andrew Nixon did not address why the Shingrix safety study was withheld. Health Secretary Robert F.
The actions come despite Kennedy’s public commitment to openness on scientific matters under his oversight at HHS. At the FDA, the withdrawal orders overrode acceptance decisions already made by independent medical journals.
Key Facts
Story Timeline
6 events- May 8, 12:03 PM ET
1 new source added: Le Monde
1 sourceLe Monde - 2025 (last fall)
Preliminary abstract of one COVID-19 vaccine study presented at a conference and remains online
1 sourceThe New York Times - Prior to May 2026
Two FDA COVID-19 vaccine studies accepted for publication at medical journals then withdrawn on orders from unnamed officials
1 sourceThe New York Times - Prior to May 2026
CDC study on COVID-19 vaccines in healthy adults scrapped after rejection by Robert F. Kennedy’s acting CDC director
1 sourceThe Washington Post - Prior to May 2026
FDA officials block submission of two Shingrix study abstracts to major drug safety conference
1 sourceThe New York Times - 2026-05-06 (Tuesday)
New York Times reports HHS confirmation that FDA blocked publication of COVID-19 and shingles vaccine studies
2 sourcesThe New York Times · Department of Health and Human Services
Potential Impact
- 01
Contradiction between Robert F. Kennedy’s radical transparency pledge and documented study withdrawals
- 02
Internal scientific manuscripts and conference abstracts remain partially available despite publication blocks
- 03
Suppression of peer-reviewed safety and efficacy findings on major vaccines may reduce public confidence in immunization programs
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…